Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
VMF
Annual Reports
NA
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Arixtra
2. Fondaparinux
3. Quixidar
1. 114870-03-0
2. Arixtra
3. Quixidar
4. Fondaparin Sodium
5. Sr-90107a
6. Org 31540
7. Sr 90107a
8. Fondaparinux Sodium For Assay
9. Org-31540
10. Fondaparinux Sodium Identification
11. X0q6n9usoz
12. Ic-851589
13. Xantidar
14. Arixtra (tn)
15. Unii-x0q6n9usoz
16. Fondaparinux Sodium [usan]
17. Fondaparinux Sodium [usan:inn:ban]
18. Gsk-576428
19. Ic 85158
20. Sr-90107
21. Chembl1200644
22. Fondaparinux Sodium [mi]
23. Fondaparinux Sodium [inn]
24. Fondaparinux Sodium [jan]
25. Dtxsid501027612
26. Fondaparinux Sodium [mart.]
27. Fondaparinux Sodium (jan/usp/inn)
28. Fondaparinux Sodium [usp-rs]
29. Fondaparinux Sodium [who-dd]
30. Natural Heparin Pentasaccharide Sodium
31. Akos005146286
32. Fondaparinux Sodium [ema Epar]
33. Ccg-270693
34. Fondaparinux Sodium [orange Book]
35. As-80003
36. Fondaparinux Sodium [usp Monograph]
37. C71476
38. D01844
39. A803253
40. Q421218
41. Alpha-d-glucopyranoside, Methyl O-2-deoxy-6-o-sulfo-2-(sulfoamino)-alpha-d-glucopyranosyl-(1-4)-o-beta-d-glucopyranuronosyl(1-4)-o-2-deoxy-3,6-di-o-sulfo-2-(sulfoamino)-alpha-d-glucopyranosyl-(1-4)-o-2-o-sulfo-alpha-l-idopyranuronosyl-(1-4)-2-deoxy-2-(sulfoamino)-, 6-(hydrogen Sulfate), Decasodium Salt
42. Decasodium 6-[6-[2-carboxylato-4-hydroxy-6-[4-hydroxy-6-methoxy-5-(sulfonatoamino)-2-(sulfonatooxymethyl)tetrahydropyran-3-yl]oxy-5-sulfonatooxy-tetrahydropyran-3-yl]oxy-5-(sulfonatoamino)-4-sulfonatooxy-2-(sulfonatooxymethyl)tetrahydropyran-3-yl]oxy-3-[4;fondaparinux Sodium
43. Methly O-2-deoxy-6-o-sulfo-2-(sulfoamino)-alpha-d-glucopyranosyl-(1-4)-o-beta-d-glucopyranuronosyl-(1-4)-o-2-deoxy-3,6-di-o-sulfo-2-(sulfoamino)-alpha-d-glucopyranosyl-(1-4)-o-2-o-sulfo-alpha-l-idopyranuronosyl-(1-4)-2-deoxy-6-o-sulfo-2-(sulfoamino)-alpha-d-glucopyranoside, Decasodium Salt
Molecular Weight | 1728.1 g/mol |
---|---|
Molecular Formula | C31H43N3Na10O49S8 |
Hydrogen Bond Donor Count | 9 |
Hydrogen Bond Acceptor Count | 52 |
Rotatable Bond Count | 20 |
Exact Mass | 1726.7707769 g/mol |
Monoisotopic Mass | 1726.7707769 g/mol |
Topological Polar Surface Area | 901 Ų |
Heavy Atom Count | 101 |
Formal Charge | 0 |
Complexity | 3330 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 25 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 11 |
1 of 4 | |
---|---|
Drug Name | Arixtra |
Drug Label | ARIXTRA (fondaparinux sodium) Injection is a sterile solution containing fondaparinux sodium. It is a synthetic and specific inhibitor of activated Factor X (Xa). Fondaparinux sodium is methyl O-2-deoxy-6-O-sulfo-2-(sulfoamino)--D-glucopyranosyl-(1... |
Active Ingredient | Fondaparinux sodium |
Dosage Form | Injectable |
Route | Subcutaneous |
Strength | 5mg/0.4ml; 2.5mg/0.5ml; 7.5mg/0.6ml; 10mg/0.8ml |
Market Status | Prescription |
Company | Agi |
2 of 4 | |
---|---|
Drug Name | Fondaparinux sodium |
PubMed Health | Fondaparinux (Injection) |
Drug Classes | Anticoagulant |
Drug Label | ARIXTRA (fondaparinux sodium) Injection is a sterile solution containing fondaparinux sodium. It is a synthetic and specific inhibitor of activated Factor X (Xa). Fondaparinux sodium is methyl O-2-deoxy-6-O-sulfo-2-(sulfoamino)--D-glucopyranosyl-(1... |
Active Ingredient | Fondaparinux sodium |
Dosage Form | Injectable |
Route | Subcutaneous |
Strength | 2.5mg/0.5ml; 7.5mg/0.6ml; 5mg/0.4ml; 10mg/0.8ml |
Market Status | Prescription |
Company | Dr Reddys Labs |
3 of 4 | |
---|---|
Drug Name | Arixtra |
Drug Label | ARIXTRA (fondaparinux sodium) Injection is a sterile solution containing fondaparinux sodium. It is a synthetic and specific inhibitor of activated Factor X (Xa). Fondaparinux sodium is methyl O-2-deoxy-6-O-sulfo-2-(sulfoamino)--D-glucopyranosyl-(1... |
Active Ingredient | Fondaparinux sodium |
Dosage Form | Injectable |
Route | Subcutaneous |
Strength | 5mg/0.4ml; 2.5mg/0.5ml; 7.5mg/0.6ml; 10mg/0.8ml |
Market Status | Prescription |
Company | Agi |
4 of 4 | |
---|---|
Drug Name | Fondaparinux sodium |
PubMed Health | Fondaparinux (Injection) |
Drug Classes | Anticoagulant |
Drug Label | ARIXTRA (fondaparinux sodium) Injection is a sterile solution containing fondaparinux sodium. It is a synthetic and specific inhibitor of activated Factor X (Xa). Fondaparinux sodium is methyl O-2-deoxy-6-O-sulfo-2-(sulfoamino)--D-glucopyranosyl-(1... |
Active Ingredient | Fondaparinux sodium |
Dosage Form | Injectable |
Route | Subcutaneous |
Strength | 2.5mg/0.5ml; 7.5mg/0.6ml; 5mg/0.4ml; 10mg/0.8ml |
Market Status | Prescription |
Company | Dr Reddys Labs |
* 1. 5-mg/0. 3-ml and 2. 5-mg/0. 5-ml solution for injection:
Prevention of venous thromboembolic events (VTE) in adults undergoing major orthopaedic surgery of the lower limbs such as hip fracture, major knee surgery or hip-replacement surgery.
Prevention of VTE in adults undergoing abdominal surgery who are judged to be at high risk of thromboembolic complications, such as patients undergoing abdominal cancer surgery.
Prevention of VTE in adult medical patients who are judged to be at high risk for VTE and who are immobilised due to acute illness such as cardiac insufficiency and / or acute respiratory disorders, and / or acute infectious or inflammatory disease.
Treatment of adults with acute symptomatic spontaneous superficial-vein thrombosis of the lower limbs without concomitant deep-vein thrombosis.
* 2. 5-mg/0. 5-ml solution for injection:
Treatment of unstable angina or non-ST-segment-elevation myocardial infarction (UA/NSTEMI) in adult patients for whom urgent (< 120 mins) invasive management (PCI) is not indicated.
infarction (STEMI) in adult patients who are managed with thrombolytics or who initially are to receive no other form of reperfusion therapy.
* 5-mg/0. 4-ml, 7. 5-mg/0. 6-ml and 10-mg/0. 8-ml solution for injection:
Treatment of adults with acute deep-vein thrombosis (DVT) and treatment of acute pulmonary embolism (PE), except in haemodynamically unstable patients or patients who require thrombolysis or pulmonary embolectomy.
1. 5 mg/0. 3 ml and 2. 5 mg/0. 5 ml, solution for injection:
Prevention of Venous Thromboembolic Events (VTE) in patients undergoing major orthopaedic surgery of the lower limbs such as hip fracture, major knee surgery or hip replacement surgery.
Prevention of Venous Thromboembolic Events (VTE) in patients undergoing abdominal surgery who are judged to be at high risk of thromboembolic complications, such as patients undergoing abdominal cancer surgery (see section 5. 1).
Prevention of Venous Thromboembolic Events (VTE) in medical patients who are judged to be at high risk for VTE and who are immobilised due to acute illness such as cardiac insufficiency and/or acute respiratory disorders, and/or acute infectious or inflammatory disease.
2. 5 mg/0. 5 ml, solution for injection:
Treatment of unstable angina or non-ST segment elevation myocardial infarction (UA/NSTEMI) in patients for whom urgent (< 120 mins) invasive management (PCI) is not indicated (see sections 4. 4 and 5. 1).
Treatment of ST segment elevation myocardial infarction (STEMI) in patients who are managed with thrombolytics or who initially are to receive no other form of reperfusion therapy.
5 mg/0. 4 ml, 7. 5 mg/0. 6 ml and 10 mg/0. 8 ml solution for injection:
Treatment of acute Deep Vein Thrombosis (DVT) and treatment of acute Pulmonary Embolism (PE), except in haemodynamically unstable patients or patients who require thrombolysis or pulmonary embolectomy.
Factor Xa Inhibitors
Endogenous factors and drugs that inhibit or block the activity of FACTOR XA. (See all compounds classified as Factor Xa Inhibitors.)
B01AX05
B01AX05
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 15259
Submission : 2001-01-22
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 28762
Submission : 2014-11-30
Status : Active
Type : II
Registrant Name : Handok Co., Ltd.
Registration Date : 2013-03-29
Registration Number : 20130329-193-I-126-01
Manufacturer Name : Aspen notre dame de bondeville@Ajinomoto Omnichem@Aspen Oss BV@ORIL Industrie
Manufacturer Address : 1, rue de l'Abbaye, 76960 Notre Dame De Bondeville@Cooppallaan 91, Wetteren, Oost-Vlaanderen, B-9230, Belgium_x000D_ (Manufacturer 1)@Kloosterstraat6 5349 AB OSS, The Netherlands_x000D_ (Manufacturer 2)@13, rue Auguste Desgenétais, BOLBEC, 76210, France
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
GDUFA
DMF Review : Reviewed
Rev. Date : 2022-04-04
Pay. Date : 2022-03-29
DMF Number : 22579
Submission : 2009-02-26
Status : Active
Type : II
Date of Issue : 2022-06-15
Valid Till : 2025-06-16
Written Confirmation Number : WC-0034
Address of the Firm :
NDC Package Code : 55111-839
Start Marketing Date : 2009-02-26
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Available Reg Filing : CA, ASMF |
Shanghai Minbiotech is the leading producer of biopharmaceuticals and a variety of high-end generic & innovative drugs.
GDUFA
DMF Review : Reviewed
Rev. Date : 2014-02-05
Pay. Date : 2013-08-30
DMF Number : 27336
Submission : 2013-09-27
Status : Active
Type : II
NDC Package Code : 57884-0026
Start Marketing Date : 2013-09-26
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (180g/180g)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 25093
Submission : 2011-06-30
Status : Active
Type : II
GDUFA
DMF Review : Reviewed
Rev. Date : 2017-02-06
Pay. Date : 2016-09-06
DMF Number : 30767
Submission : 2016-07-15
Status : Active
Type : II
NDC Package Code : 62227-006
Start Marketing Date : 2019-02-01
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : Reviewed
Rev. Date : 2023-02-03
Pay. Date : 2022-12-12
DMF Number : 37729
Submission : 2022-12-16
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 28584
Submission : 2014-08-26
Status : Active
Type : II
NDC Package Code : 65897-1012
Start Marketing Date : 2022-12-06
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 15259
Submission : 2001-01-22
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 28762
Submission : 2014-11-30
Status : Active
Type : II
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
GDUFA
DMF Review : Complete
Rev. Date : 2022-04-04
Pay. Date : 2022-03-29
DMF Number : 22579
Submission : 2009-02-26
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2014-07-14
Pay. Date : 2014-01-22
DMF Number : 27873
Submission : 2014-01-28
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 27475
Submission : 2013-09-17
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 15257
Submission : 2001-01-19
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 28584
Submission : 2014-08-26
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2014-02-05
Pay. Date : 2013-08-30
DMF Number : 27336
Submission : 2013-09-27
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 25093
Submission : 2011-06-30
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2014-04-07
Pay. Date : 2013-09-26
DMF Number : 27563
Submission : 2013-12-30
Status : Active
Type : II
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
95
PharmaCompass offers a list of Fondaparinux Sodium API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Fondaparinux Sodium manufacturer or Fondaparinux Sodium supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Fondaparinux Sodium manufacturer or Fondaparinux Sodium supplier.
PharmaCompass also assists you with knowing the Fondaparinux Sodium API Price utilized in the formulation of products. Fondaparinux Sodium API Price is not always fixed or binding as the Fondaparinux Sodium Price is obtained through a variety of data sources. The Fondaparinux Sodium Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Arixtra manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Arixtra, including repackagers and relabelers. The FDA regulates Arixtra manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Arixtra API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Arixtra manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Arixtra supplier is an individual or a company that provides Arixtra active pharmaceutical ingredient (API) or Arixtra finished formulations upon request. The Arixtra suppliers may include Arixtra API manufacturers, exporters, distributors and traders.
click here to find a list of Arixtra suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Arixtra DMF (Drug Master File) is a document detailing the whole manufacturing process of Arixtra active pharmaceutical ingredient (API) in detail. Different forms of Arixtra DMFs exist exist since differing nations have different regulations, such as Arixtra USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Arixtra DMF submitted to regulatory agencies in the US is known as a USDMF. Arixtra USDMF includes data on Arixtra's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Arixtra USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Arixtra suppliers with USDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Arixtra Drug Master File in Korea (Arixtra KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Arixtra. The MFDS reviews the Arixtra KDMF as part of the drug registration process and uses the information provided in the Arixtra KDMF to evaluate the safety and efficacy of the drug.
After submitting a Arixtra KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Arixtra API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Arixtra suppliers with KDMF on PharmaCompass.
A Arixtra written confirmation (Arixtra WC) is an official document issued by a regulatory agency to a Arixtra manufacturer, verifying that the manufacturing facility of a Arixtra active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Arixtra APIs or Arixtra finished pharmaceutical products to another nation, regulatory agencies frequently require a Arixtra WC (written confirmation) as part of the regulatory process.
click here to find a list of Arixtra suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Arixtra as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Arixtra API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Arixtra as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Arixtra and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Arixtra NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Arixtra suppliers with NDC on PharmaCompass.
Arixtra Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Arixtra GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Arixtra GMP manufacturer or Arixtra GMP API supplier for your needs.
A Arixtra CoA (Certificate of Analysis) is a formal document that attests to Arixtra's compliance with Arixtra specifications and serves as a tool for batch-level quality control.
Arixtra CoA mostly includes findings from lab analyses of a specific batch. For each Arixtra CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Arixtra may be tested according to a variety of international standards, such as European Pharmacopoeia (Arixtra EP), Arixtra JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Arixtra USP).